EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.

Somayeh MohammadpourHamed R GoodarziMojtaba JafariniaMohammad A PorhoseingholiEhsan Nazemalhosseini Mojarad

Published in: Journal of cellular physiology (2019)

There is a link between EMAST and reduced nuclear expression of MSH3. There is worse survival in patients with EMAST+ CRC after 5-FU-based chemotherapy. According to our findings, adjuvant 5-FU-based chemotherapy might not be advantageous in EMAST+ CRCs with Stage II or III disease.

Keyphrases

locally advanced
poor prognosis
early stage
binding protein
radiation therapy
chemotherapy induced